静脉-动脉体外膜氧合治疗心脏骤停后休克:一项观察性研究与倾向性评分分析
该研究基于大型区域登记数据,纳入2988例心脏骤停后入住ICU的患者,其中1489例发生心脏骤停后休克。52例(3.5%)接受VA-ECMO治疗,多为缺血性病因(67%)。心脏骤停后休克患者中312例(21%)存活出院,VA-ECMO组25% vs 对照组21%(P=0.45),校正院前和院内因素后生存无显著差异(OR=0.9,95%CI 0.4-2.3,P=0.84),倾向性评分匹配后结果一致。在VA-ECMO患者中,初始动脉pH(每升高0.1,OR=1.7,95%CI 1.0-2.8,P=0.04)和ROSC后超过24小时植入VA-ECMO(OR=20.0,95%CI 1.4-277.3,P=0.03)与生存相关。作者认为,在选定患者中使用VA-ECMO可能是合适的治疗。
要点
- 心脏骤停后休克发生率高(1489/2988),存活出院率仅21%(312/1489)。
- VA-ECMO组存活出院25% vs 对照组21%,差异未达统计学显著(P=0.45)。
- 校正院前和院内因素后,VA-ECMO与生存无显著差异(OR=0.9,95%CI 0.4-2.3,P=0.84),倾向性评分匹配后结果一致。
- VA-ECMO患者中,初始动脉pH每升高0.1,生存OR=1.7(95%CI 1.0-2.8,P=0.04)。
- VA-ECMO患者中,ROSC后超过24小时植入VA-ECMO与生存相关(OR=20.0,95%CI 1.4-277.3,P=0.03)。
适用人群与场景
- 心脏骤停后入住ICU并发生心脏骤停后休克的患者。
- 研究纳入2988例心脏骤停后入住ICU患者中的1489例发生心脏骤停后休克者,多数为男性(68%),平均年龄63岁(SD=15)。
研究设计与关键结果
- 研究类型为观察性研究,基于大型区域登记数据,纳入2988例心脏骤停后入住ICU患者,其中1489例发生心脏骤停后休克并纳入分析。
- 52例(3.5%)接受VA-ECMO治疗,其中缺血性病因占67%。
- 心脏骤停后休克患者中312例(21%)存活出院,VA-ECMO组25% vs 对照组21%(P=0.45)。
- 校正院前和院内因素后,VA-ECMO组与对照组生存无显著差异(OR=0.9,95%CI 0.4-2.3,P=0.84);倾向性评分匹配后结果一致。
- 在VA-ECMO患者中,初始动脉pH每升高0.1,生存OR=1.7(95%CI 1.0-2.8,P=0.04)。
- 在VA-ECMO患者中,ROSC后超过24小时植入VA-ECMO与生存相关(OR=20.0,95%CI 1.4-277.3,P=0.03)。
证据类型、等级与局限
- 证据类型:观察性研究,采用逻辑回归和倾向性评分分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在选定患者中使用VA-ECMO可能是合适的治疗。
- VA-ECMO患者中初始动脉pH较高和ROSC后超过24小时植入VA-ECMO与生存相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Cardiogenic shock due to post-resuscitation myocardial dysfunction is a major cause of mortality among patients hospitalized after cardiac arrest (CA). Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been proposed in the most severe cases but the level of evidence is very low. We assessed characteristics, outcome and prognostic factors of patients treated with VA-ECMO for post-CA shock.
METHODS: Using a large regional registry, we focused on all CA admitted in ICU. Among those who developed a post-CA shock, prognostic was compared according to VA-ECMO use, using logistic regression and propensity score. Specific prognostic factors were identified among VA-ECMO patients.
RESULTS: Among 2988 patients admitted after CA, 1489 developed a post-CA shock, and were included. They were mostly male (68%), with mean age 63 years (SD=15). Fiflty-two patients (3.5%) were treated with VA-ECMO, mostly patients with ischemic cause of CA (67%). Among patients with post-CA shock, 312 (21%) were discharged alive (25% in VA-ECMO group, 21% in control group, P=0.45). After adjustment for pre-hospital and in-hospital factors, survival did not differ among patients treated with VA-ECMO (OR for survival=0.9, 95%CI 0.4-2.3, P=0.84). After propensity-score matching, results were consistent. Among patients treated with VA-ECMO, initial arterial pH (OR=1.7 per 0.1 increase, 95%CI 1.0-2.8, P=0.04) and implantation of VA-ECMO over 24h after ROSC (OR=20.0, 95%CI 1.4-277.3, P=0.03) were associated with survival.
CONCLUSIONS: Post-CA shock is frequent and is associated with a high mortality rate. When used in selected patients, we observed that VA-ECMO could be an appropriate treatment.
参考来源
- Bougouin W, Aissaoui N, Combes A, et al. Post-cardiac arrest shock treated with veno-arterial extracorporeal membrane oxygenation: An observational study and propensity-score analysis. Resuscitation. 2016. PMID: 27865776. doi:10.1016/j.resuscitation.2016.11.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。